Kelso Pharma, the escalating speciality pharma company, has appointed senior Existence Sciences executive, Gordon Cameron OBE, as its Non-Govt Chairman.
A senior executive with 25 years’ Board-stage practical experience in personal fairness and plc shown companies, Gordon has labored in the Uk and US, principally in biotech and pharmaceutical services which includes equally agreement exploration organisations (CRO) and agreement advancement and producing organisations (CDMO). Initially with Ernst & Young, Gordon experienced many many years in investment decision banking with Rothschild right before turning into CFO and then CEO of FTSE-250 global vaccines corporation, Acambis plc. Gordon has spent the final 15 many years as CFO with Quotient Sciences, a non-public-equity backed worldwide CDMO and CRO. During his time there, revenues grew 15-fold.
Kelso Pharma, dependent in the Scottish Borders city of the exact same identify, aims to deliver modern, worth-extra, specialty medicines to the European health care markets, giving medicines that increase the life of individuals in a value-helpful and ethical method. Kelso Pharma is expanding via a mix of company & product acquisitions, partnerships and organic expansion, both of those in the United kingdom and in Europe.
Commenting on the appointment, Kelso Pharma CEO, Dr. Tom Stratford, mentioned: “We’re thrilled to welcome Gordon to the Kelso Pharma crew as our Non-Executive Chairman. He provides comprehensive market encounter, as nicely as a deep comprehension of rising enterprises under personal fairness ownership.
“Gordon’s working experience, skillset and information show the calibre of people we’re seeking to perform with at Kelso Pharma. We intention to present medications that strengthen the lives of individuals on a each day basis and we appear forward to functioning with Gordon as we continue to expand the small business.”
Gordon Cameron extra: “I’m extremely psyched to be joining Kelso Pharma at a occupied and pivotal time for the small business as they look to grow, both organically and by acquisition.
“With the goal of offering price-extra medicines to the market in an ethical method with persons at the coronary heart of choice generating aligns with my very own values and I’m looking forward to participating in a part in driving Kelso Pharma’s expansion.”